FGF19 is however, also a strong inducer of liver carcinomas in mice (108) and it is of high importance to mitigate the mitogenic, FGFR4-mediated effect of FGF19 to allow human therapy, even though species difference may indicate that FGF19 is less mitogenic in human cellular systems (109, 110). This evidence concerns the gene FGF19 and hepatocellular carcinoma.